Exchange Traded Concepts LLC Increases Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Exchange Traded Concepts LLC lifted its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 9.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 41,866 shares of the company’s stock after buying an additional 3,740 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Autolus Therapeutics were worth $152,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of AUTL. ProShare Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $43,000. Daiwa Securities Group Inc. raised its holdings in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after buying an additional 15,293 shares during the period. Herbst Group LLC purchased a new stake in shares of Autolus Therapeutics during the 3rd quarter valued at about $91,000. Bayesian Capital Management LP purchased a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $108,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $4.52 on Tuesday. The company has a market cap of $1.20 billion, a P/E ratio of -3.77 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. Autolus Therapeutics plc has a one year low of $2.21 and a one year high of $7.45. The business’s 50-day simple moving average is $3.96 and its 200 day simple moving average is $4.10.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, sell-side analysts forecast that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.